Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 783 entries
Sorted by: Best Match Show Resources per page
Antibody based immunotherapy for multiple myeloma: it's about time.

Leukemia & lymphoma

Sher T, Gertz MA.
PMID: 26373636
Leuk Lymphoma. 2016 Feb;57(2):269-275. doi: 10.3109/10428194.2015.1092530. Epub 2015 Dec 16.

Monoclonal antibodies have made an indelible impact on cancer practice. Historically multiple myeloma (MM) has lagged behind in benefitting from this treatment modality. Recent years have seen a tremendous increase in the number of therapeutic antibodies being developed for...

Cite
Sher T, Gertz MA. Antibody based immunotherapy for multiple myeloma: it's about time. Leuk Lymphoma. 2015;57(2):269-275doi: 10.3109/10428194.2015.1092530.
Sher, T., & Gertz, M. A. (2016). Antibody based immunotherapy for multiple myeloma: it's about time. Leukemia & lymphoma, 57(2), 269-275. https://doi.org/10.3109/10428194.2015.1092530
Sher, Taimur, and Gertz, Morie A. "Antibody based immunotherapy for multiple myeloma: it's about time." Leukemia & lymphoma vol. 57,2 (2016): 269-275. doi: https://doi.org/10.3109/10428194.2015.1092530
Sher T, Gertz MA. Antibody based immunotherapy for multiple myeloma: it's about time. Leuk Lymphoma. 2016 Feb;57(2):269-275. doi: 10.3109/10428194.2015.1092530. Epub 2015 Dec 16. PMID: 26373636.
Copy Download .nbib Format: NLM
Corrigendum.

Leukemia & lymphoma

[No authors listed]
PMID: 27063029
Leuk Lymphoma. 2016 May;57(5):1246. doi: 10.3109/10428194.2016.1157317. Epub 2016 Apr 11.

No abstract available.

Cite
Corrigendum. Leuk Lymphoma. 2016;57(5):1246doi: 10.3109/10428194.2016.1157317.
(2016). Corrigendum. Leukemia & lymphoma, 57(5), 1246. https://doi.org/10.3109/10428194.2016.1157317
"Corrigendum." Leukemia & lymphoma vol. 57,5 (2016): 1246. doi: https://doi.org/10.3109/10428194.2016.1157317
Corrigendum. Leuk Lymphoma. 2016 May;57(5):1246. doi: 10.3109/10428194.2016.1157317. Epub 2016 Apr 11. PMID: 27063029.
Copy Download .nbib Format: NLM
Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network.

Leukemia & lymphoma

Mannu C, Gazzola A, Ciabatti E, Fuligni F, Cavalli M, Della Starza I, Genuardi E, Mantoan B, Monitillo L, Del Giudice I, Ladetto M, Gaidano G, Sabattini E, Pileri SA, Galimberti S, Piccaluga PP.
PMID: 25115509
Leuk Lymphoma. 2016 Feb;57(2):400-410. doi: 10.3109/10428194.2014.914199. Epub 2015 Mar 11.

Genomic DNA extraction is a primary component of genomic research and diagnostic routine analysis. Recently, the importance of this process has been highlighted by the necessity to standardize the diagnostic procedure. In this regard, the Minimal Residual Disease (MRD)...

Cite
Mannu C, Gazzola A, Ciabatti E, et al. Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network. Leuk Lymphoma. 2015;57(2):400-410doi: 10.3109/10428194.2014.914199.
Mannu, C., Gazzola, A., Ciabatti, E., Fuligni, F., Cavalli, M., Della Starza, I., Genuardi, E., Mantoan, B., Monitillo, L., Del Giudice, I., Ladetto, M., Gaidano, G., Sabattini, E., Pileri, S. A., Galimberti, S., Piccaluga, P. P. (2016). Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network. Leukemia & lymphoma, 57(2), 400-410. https://doi.org/10.3109/10428194.2014.914199
Mannu, Claudia, et al. "Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network." Leukemia & lymphoma vol. 57,2 (2016): 400-410. doi: https://doi.org/10.3109/10428194.2014.914199
Mannu C, Gazzola A, Ciabatti E, Fuligni F, Cavalli M, Della Starza I, Genuardi E, Mantoan B, Monitillo L, Del Giudice I, Ladetto M, Gaidano G, Sabattini E, Pileri SA, Galimberti S, Piccaluga PP. Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network. Leuk Lymphoma. 2016 Feb;57(2):400-410. doi: 10.3109/10428194.2014.914199. Epub 2015 Mar 11. PMID: 25115509.
Copy Download .nbib Format: NLM
Wang, S.-Y., Chen, W.-L., Wang, Z.-C., et al. High expression of FAMLF is associated with clinical response in patients with de novo acute myeloid leukemia. Leuk. Lymphoma 2016. http://dx.doi.org/10.3109/10428194.2016.1160087.

Leukemia & lymphoma

[No authors listed]
PMID: 27185301
Leuk Lymphoma. 2017 Feb;58(2):505. doi: 10.1080/10428194.2016.1183917. Epub 2016 May 17.

No abstract available.

Cite
Wang, S.-Y., Chen, W.-L., Wang, Z.-C., et al. High expression of FAMLF is associated with clinical response in patients with de novo acute myeloid leukemia. Leuk. Lymphoma 2016. http://dx.doi.org/10.3109/10428194.2016.1160087. Leuk Lymphoma. 2016;58(2):505doi: 10.1080/10428194.2016.1183917.
(2017). Wang, S.-Y., Chen, W.-L., Wang, Z.-C., et al. High expression of FAMLF is associated with clinical response in patients with de novo acute myeloid leukemia. Leuk. Lymphoma 2016. http://dx.doi.org/10.3109/10428194.2016.1160087. Leukemia & lymphoma, 58(2), 505. https://doi.org/10.1080/10428194.2016.1183917
"Wang, S.-Y., Chen, W.-L., Wang, Z.-C., et al. High expression of FAMLF is associated with clinical response in patients with de novo acute myeloid leukemia. Leuk. Lymphoma 2016. http://dx.doi.org/10.3109/10428194.2016.1160087." Leukemia & lymphoma vol. 58,2 (2017): 505. doi: https://doi.org/10.1080/10428194.2016.1183917
Wang, S.-Y., Chen, W.-L., Wang, Z.-C., et al. High expression of FAMLF is associated with clinical response in patients with de novo acute myeloid leukemia. Leuk. Lymphoma 2016. http://dx.doi.org/10.3109/10428194.2016.1160087. Leuk Lymphoma. 2017 Feb;58(2):505. doi: 10.1080/10428194.2016.1183917. Epub 2016 May 17. PMID: 27185301.
Copy Download .nbib Format: NLM
Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients.

Leukemia & lymphoma

Fernandez-Alvarez R, Gonzalez-Rodriguez AP, Rubio-Castro A, Gonzalez ME, Payer AR, Alonso-Garcia A, Rodriguez-Villar D, Dominguez-Iglesias F, Sancho JM.
PMID: 25976108
Leuk Lymphoma. 2016 Feb;57(2):463-466. doi: 10.3109/10428194.2015.1050666. Epub 2015 Jun 18.

No abstract available.

Cite
Fernandez-Alvarez R, Gonzalez-Rodriguez AP, Rubio-Castro A, et al. Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients. Leuk Lymphoma. 2015;57(2):463-466doi: 10.3109/10428194.2015.1050666.
Fernandez-Alvarez, R., Gonzalez-Rodriguez, A. P., Rubio-Castro, A., Gonzalez, M. E., Payer, A. R., Alonso-Garcia, A., Rodriguez-Villar, D., Dominguez-Iglesias, F., & Sancho, J. M. (2016). Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients. Leukemia & lymphoma, 57(2), 463-466. https://doi.org/10.3109/10428194.2015.1050666
Fernandez-Alvarez, Ruben, et al. "Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients." Leukemia & lymphoma vol. 57,2 (2016): 463-466. doi: https://doi.org/10.3109/10428194.2015.1050666
Fernandez-Alvarez R, Gonzalez-Rodriguez AP, Rubio-Castro A, Gonzalez ME, Payer AR, Alonso-Garcia A, Rodriguez-Villar D, Dominguez-Iglesias F, Sancho JM. Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients. Leuk Lymphoma. 2016 Feb;57(2):463-466. doi: 10.3109/10428194.2015.1050666. Epub 2015 Jun 18. PMID: 25976108.
Copy Download .nbib Format: NLM
Generic Imatinib: The real-deal or just a deal?.

Leukemia & lymphoma

Mathews V.
PMID: 24828873
Leuk Lymphoma. 2014 May 14;1-8. doi: 10.3109/10428194.2014.922183. Epub 2014 May 14.

No abstract available.

Cite
Mathews V. Generic Imatinib: The real-deal or just a deal?. Leuk Lymphoma. 2014;1-8doi: 10.3109/10428194.2014.922183.
Mathews, V. (2014). Generic Imatinib: The real-deal or just a deal?. Leukemia & lymphoma, 1-8. https://doi.org/10.3109/10428194.2014.922183
Mathews, Vikram. "Generic Imatinib: The real-deal or just a deal?." Leukemia & lymphoma vol. (2014): 1-8. doi: https://doi.org/10.3109/10428194.2014.922183
Mathews V. Generic Imatinib: The real-deal or just a deal?. Leuk Lymphoma. 2014 May 14;1-8. doi: 10.3109/10428194.2014.922183. Epub 2014 May 14. PMID: 24828873.
Copy Download .nbib Format: NLM
Survival of de novo and secondary acute promyelocytic leukemia: a propensity-matched analysis of the SEER database.

Leukemia & lymphoma

Giri S, Pathak R, Martin MG, Bhatt VR.
PMID: 26084205
Leuk Lymphoma. 2016 Feb;57(2):385-391. doi: 10.3109/10428194.2015.1063142. Epub 2015 Jul 25.

Prior studies demonstrated that secondary acute promyelocytic leukemia (sAPL) and de novo APL may but not consistently have similar overall survival (OS). We used the Surveillance, Epidemiology, and End Results (SEER) 13 database to compare their OS. Patients with...

Cite
Giri S, Pathak R, Martin MG, et al. Survival of de novo and secondary acute promyelocytic leukemia: a propensity-matched analysis of the SEER database. Leuk Lymphoma. 2015;57(2):385-391doi: 10.3109/10428194.2015.1063142.
Giri, S., Pathak, R., Martin, M. G., & Bhatt, V. R. (2016). Survival of de novo and secondary acute promyelocytic leukemia: a propensity-matched analysis of the SEER database. Leukemia & lymphoma, 57(2), 385-391. https://doi.org/10.3109/10428194.2015.1063142
Giri, Smith, et al. "Survival of de novo and secondary acute promyelocytic leukemia: a propensity-matched analysis of the SEER database." Leukemia & lymphoma vol. 57,2 (2016): 385-391. doi: https://doi.org/10.3109/10428194.2015.1063142
Giri S, Pathak R, Martin MG, Bhatt VR. Survival of de novo and secondary acute promyelocytic leukemia: a propensity-matched analysis of the SEER database. Leuk Lymphoma. 2016 Feb;57(2):385-391. doi: 10.3109/10428194.2015.1063142. Epub 2015 Jul 25. PMID: 26084205.
Copy Download .nbib Format: NLM
Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy.

Leukemia & lymphoma

O'Brian K, Luo S, Ganti A, Riedell P, Lynch RC, Roop R, Sanfilippo KM, Liu W, Colditz GA, Carson KR.
PMID: 26085202
Leuk Lymphoma. 2016 Feb;57(2):313-319. doi: 10.3109/10428194.2015.1056183. Epub 2015 Jul 25.

Identifying weight changes associated with treatment of diffuse large B-cell lymphoma (DLBCL) has the potential to improve the long-term health of survivors. A retrospective cohort of United States veterans with a new diagnosis of DLBCL between October 1, 1998...

Cite
O'Brian K, Luo S, Ganti A, et al. Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy. Leuk Lymphoma. 2015;57(2):313-319doi: 10.3109/10428194.2015.1056183.
O'Brian, K., Luo, S., Ganti, A., Riedell, P., Lynch, R. C., Roop, R., Sanfilippo, K. M., Liu, W., Colditz, G. A., & Carson, K. R. (2016). Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy. Leukemia & lymphoma, 57(2), 313-319. https://doi.org/10.3109/10428194.2015.1056183
O'Brian, Katiuscia, et al. "Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy." Leukemia & lymphoma vol. 57,2 (2016): 313-319. doi: https://doi.org/10.3109/10428194.2015.1056183
O'Brian K, Luo S, Ganti A, Riedell P, Lynch RC, Roop R, Sanfilippo KM, Liu W, Colditz GA, Carson KR. Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy. Leuk Lymphoma. 2016 Feb;57(2):313-319. doi: 10.3109/10428194.2015.1056183. Epub 2015 Jul 25. PMID: 26085202; PMCID: PMC4752439.
Copy Download .nbib Format: NLM
The effect of extracorporeal photopheresis on T cell response in chronic graft-versus-host disease.

Leukemia & lymphoma

Zhu L, Couriel DR, Chang CH.
PMID: 26059058
Leuk Lymphoma. 2016 Feb;57(2):376-384. doi: 10.3109/10428194.2015.1057893. Epub 2015 Jul 18.

Extracorporeal photopheresis (ECP) is a safe and effective immunoregulatory therapy for steroid-refractory chronic graft-versus-host disease (cGVHD) but its mechanism of action is poorly understood. In this study, we evaluated the effect of ECP in a sample of cGVHD patients....

Cite
Zhu L, Couriel DR, Chang CH. The effect of extracorporeal photopheresis on T cell response in chronic graft-versus-host disease. Leuk Lymphoma. 2015;57(2):376-384doi: 10.3109/10428194.2015.1057893.
Zhu, L., Couriel, D. R., & Chang, C. H. (2016). The effect of extracorporeal photopheresis on T cell response in chronic graft-versus-host disease. Leukemia & lymphoma, 57(2), 376-384. https://doi.org/10.3109/10428194.2015.1057893
Zhu, Lingqiao, et al. "The effect of extracorporeal photopheresis on T cell response in chronic graft-versus-host disease." Leukemia & lymphoma vol. 57,2 (2016): 376-384. doi: https://doi.org/10.3109/10428194.2015.1057893
Zhu L, Couriel DR, Chang CH. The effect of extracorporeal photopheresis on T cell response in chronic graft-versus-host disease. Leuk Lymphoma. 2016 Feb;57(2):376-384. doi: 10.3109/10428194.2015.1057893. Epub 2015 Jul 18. PMID: 26059058.
Copy Download .nbib Format: NLM
Exploring the role of bone marrow increased FDG uptake on PET/CT in patients with lymphoma-associated hemophagocytic lymphohistiocytosis: a reflection of bone marrow involvement or cytokine storm?.

Leukemia & lymphoma

Yang YQ, Ding CY, Xu J, Fan L, Wang L, Tian T, Li TN, Li JY, Xu W.
PMID: 25989865
Leuk Lymphoma. 2016 Feb;57(2):291-298. doi: 10.3109/10428194.2015.1048442. Epub 2015 Jun 19.

The role of 18F-2-fluoro-2-deoxy-D-glucose (FDG) uptake of bone marrow (BM) on positron emission tomography/computed tomography (PET/CT) in patients with lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH) remains uncertain. This retrospective study included 34 LA-HLH patients who underwent both PET/CT and comprehensive BM...

Cite
Yang YQ, Ding CY, Xu J, et al. Exploring the role of bone marrow increased FDG uptake on PET/CT in patients with lymphoma-associated hemophagocytic lymphohistiocytosis: a reflection of bone marrow involvement or cytokine storm?. Leuk Lymphoma. 2015;57(2):291-298doi: 10.3109/10428194.2015.1048442.
Yang, Y. Q., Ding, C. Y., Xu, J., Fan, L., Wang, L., Tian, T., Li, T. N., Li, J. Y., & Xu, W. (2016). Exploring the role of bone marrow increased FDG uptake on PET/CT in patients with lymphoma-associated hemophagocytic lymphohistiocytosis: a reflection of bone marrow involvement or cytokine storm?. Leukemia & lymphoma, 57(2), 291-298. https://doi.org/10.3109/10428194.2015.1048442
Yang, Yu-Qiong, et al. "Exploring the role of bone marrow increased FDG uptake on PET/CT in patients with lymphoma-associated hemophagocytic lymphohistiocytosis: a reflection of bone marrow involvement or cytokine storm?." Leukemia & lymphoma vol. 57,2 (2016): 291-298. doi: https://doi.org/10.3109/10428194.2015.1048442
Yang YQ, Ding CY, Xu J, Fan L, Wang L, Tian T, Li TN, Li JY, Xu W. Exploring the role of bone marrow increased FDG uptake on PET/CT in patients with lymphoma-associated hemophagocytic lymphohistiocytosis: a reflection of bone marrow involvement or cytokine storm?. Leuk Lymphoma. 2016 Feb;57(2):291-298. doi: 10.3109/10428194.2015.1048442. Epub 2015 Jun 19. PMID: 25989865.
Copy Download .nbib Format: NLM
Huang PY, mactier S, armacki N, et al. Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leuk lymphoma 2016;57:1033-1043. http://dx.doi.org/10.3109/10428194.2015.1094692.

Leukemia & lymphoma

[No authors listed]
PMID: 26674387
Leuk Lymphoma. 2016 May;57(5):I. doi: 10.3109/10428194.2015.1126438. Epub 2015 Dec 16.

No abstract available.

Cite
Huang PY, mactier S, armacki N, et al. Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leuk lymphoma 2016;57:1033-1043. http://dx.doi.org/10.3109/10428194.2015.1094692. Leuk Lymphoma. 2015;57(5):Idoi: 10.3109/10428194.2015.1126438.
(2016). Huang PY, mactier S, armacki N, et al. Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leuk lymphoma 2016;57:1033-1043. http://dx.doi.org/10.3109/10428194.2015.1094692. Leukemia & lymphoma, 57(5), I. https://doi.org/10.3109/10428194.2015.1126438
"Huang PY, mactier S, armacki N, et al. Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leuk lymphoma 2016;57:1033-1043. http://dx.doi.org/10.3109/10428194.2015.1094692." Leukemia & lymphoma vol. 57,5 (2016): I. doi: https://doi.org/10.3109/10428194.2015.1126438
Huang PY, mactier S, armacki N, et al. Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leuk lymphoma 2016;57:1033-1043. http://dx.doi.org/10.3109/10428194.2015.1094692. Leuk Lymphoma. 2016 May;57(5):I. doi: 10.3109/10428194.2015.1126438. Epub 2015 Dec 16. PMID: 26674387.
Copy Download .nbib Format: NLM
The use of Bruton's tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma.

Leukemia & lymphoma

Furtado M, Clarke K, Medd P, Hunter H, Rule S.
PMID: 25994793
Leuk Lymphoma. 2016 Feb;57(2):461-462. doi: 10.3109/10428194.2015.1050665. Epub 2015 Jun 19.

No abstract available.

Cite
Furtado M, Clarke K, Medd P, et al. The use of Bruton's tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma. Leuk Lymphoma. 2015;57(2):461-462doi: 10.3109/10428194.2015.1050665.
Furtado, M., Clarke, K., Medd, P., Hunter, H., & Rule, S. (2016). The use of Bruton's tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma. Leukemia & lymphoma, 57(2), 461-462. https://doi.org/10.3109/10428194.2015.1050665
Furtado, Michelle, et al. "The use of Bruton's tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma." Leukemia & lymphoma vol. 57,2 (2016): 461-462. doi: https://doi.org/10.3109/10428194.2015.1050665
Furtado M, Clarke K, Medd P, Hunter H, Rule S. The use of Bruton's tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma. Leuk Lymphoma. 2016 Feb;57(2):461-462. doi: 10.3109/10428194.2015.1050665. Epub 2015 Jun 19. PMID: 25994793.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 783 entries